Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T22:48:51.851Z.
Consensus retrieved: 2026-10-06T18:14:16.907Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:48:51.851Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e5b22bec38318fdeba07533daebf1876a752163d7d28918210f347f826af404f
Forward PE Ratio (N/A) = Dated Quote Price ($2.67) / Consensus Forward EPS ($-2.08)
FORWARD PE RATIO
N/A
Zentalis Pharmaceuticals, Inc.
Market Cap
$190.07M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | $190.07M | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.11M | N/A |
| RxSight, Inc. (RXST)vs › | $192.49M | N/A |
| Surrozen, Inc. (SRZN)vs › | $197.18M | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $182.60M | N/A |
| Exagen Inc. (XGN)vs › | $197.87M | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $198.33M | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $180.47M | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $179.75M | N/A |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $179.26M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.67, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.08 | $-2.36 – $-1.35 | 8 | n/m |
| 2027-12-31 | $-1.93 | $-2.41 – $-1.44 | 8 | n/m |
| 2028-12-31 | $-1.78 | $-2.68 – $-1.11 | 9 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
